|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007138,
umls-concept:C0008976,
umls-concept:C0021735,
umls-concept:C0023981,
umls-concept:C0034656,
umls-concept:C0199176,
umls-concept:C0332391,
umls-concept:C0439231,
umls-concept:C0442124,
umls-concept:C0699885,
umls-concept:C1274040,
umls-concept:C1306673,
umls-concept:C1421834,
umls-concept:C1522577
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-3-14
|
|
pubmed:abstractText |
To assess the intravesical efficacy of 60 million units of interferon (IFN) alpha-2b in preventing recurrences of Stage pT1 transitional cell carcinoma of the bladder, as well as to assess its local and systemic toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0090-4295
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
187-90
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9037279-Administration, Intravesical,
pubmed-meshheading:9037279-Antineoplastic Agents,
pubmed-meshheading:9037279-Carcinoma, Transitional Cell,
pubmed-meshheading:9037279-Double-Blind Method,
pubmed-meshheading:9037279-Female,
pubmed-meshheading:9037279-Follow-Up Studies,
pubmed-meshheading:9037279-Humans,
pubmed-meshheading:9037279-Interferon-alpha,
pubmed-meshheading:9037279-Male,
pubmed-meshheading:9037279-Middle Aged,
pubmed-meshheading:9037279-Neoplasm Recurrence, Local,
pubmed-meshheading:9037279-Neoplasm Staging,
pubmed-meshheading:9037279-Prospective Studies,
pubmed-meshheading:9037279-Recombinant Proteins,
pubmed-meshheading:9037279-Time Factors,
pubmed-meshheading:9037279-Urinary Bladder Neoplasms
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder.
|
|
pubmed:affiliation |
Urology Department, Valdecilla University Hospital, Medical School, University of Cantabria, Santander, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
